Praxis reports 100% response rate in PRAX-628 Phase 2a epilepsy PPR study; plans focal onset trial H2 2024

Praxis Precision Medicines, Inc.

15 mg cohort: 100% total response (20% partial, 80% complete); 45 mg cohort: 100% complete response.
Combined cohort: 88% complete response, 12% partial response; 8 of 9 evaluable patients responded.
Safety consistent with Phase 1; pharmacokinetic analysis confirmed therapeutic exposures.
Company plans to initiate a focal onset epilepsy efficacy study in second half of 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.